


Wharton's jelly found to halt diabetes progression in Phase II trial

June 2 2023, by Justin Jackson



(a) Percentage Δ -change in C-peptide AUC (0–120 min) for the MMTT comparison between baseline (before treatment) and 12 months after treatment, at the day 372 visit. A comparison of participants treated in part A of the study (dose escalation study) was performed. Participants receiving high-dose ProTrans (n=3) demonstrated a maintenance of their % Δ AUC compared with participants treated with low-dose ProTrans (n=3; p=0.02, Mann–Whitney test). (b) % Δ -change in C-peptide AUC (0–120 min) for the MMTT comparison between baseline (before treatment) and 12 months after treatment, at the day 372 visit, for participants in part B of the study (ProTrans treatment, n=10; placebo, n=5). ProTrans showed a statistically significant effect compared with placebo (p=0.02, Mann–Whitney test). (c) Δ -change in daily insulin requirements in participants included in part B of the study, before treatment compared with 12 months after treatment. ProTrans showed a statistically significant effect compared with placebo (p=0.05, Student's unpaired two-tailed



t test). All data are presented as box and whisker plots min. to max. *p

Citation: Wharton's jelly found to halt diabetes progression in Phase II trial (2023, June 2) retrieved 9 May 2024 from

https://medicalxpress.com/news/2023-06-wharton-jelly-halt-diabetes-phase.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.